Kite Pharma Inc


Kite Pharma Inc (KITE): FDA Approval of Kymriah Is Good News for the Future of Axi-cel

Canaccord Positive on Safety Profile of Kite’s Axi-Cel

Biotech World’s Big M&A Frenzy: Kite Pharma Inc (KITE), Gilead Sciences, Inc. (GILD), Juno Therapeutics Inc (JUNO)

How Has a Deal Between Kite and Gilead Likewise Sent Juno Shares Jumping?

Joel Greenblatt Pulls the Trigger on Kite Pharma Inc (KITE), Immunomedics, Inc. (IMMU) and Valeant Pharmaceuticals Intl Inc (VRX)

Greenblatt’s Gotham Management Turns Bullish on These 3 Biotech Stocks

Valeant Pharmaceuticals Intl Inc Not Quite Through the Woods Yet, Kite Pharma Vaulting to Green Light

Valeant’s Strengths Are Laced with Challenges Valeant Pharmaceuticals Intl Inc (NYSE:VRX) delivered a sound second-quarter print yesterday before the bell- but the troubled …

Biotech Scoop: Valeant Pharmaceuticals Intl Inc (VRX), Teva Pharmaceutical (TEVA), and Kite Pharma (KITE)

Valeant’s Siliq Not Competitive Enough in Psoriasis Market Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) fighting chances in the drug arena to compete may have just …

BTIG Gets Bullish on Kite Pharma Inc (KITE) and Axi-Cel’s Pathway to Approval in DLBCL

BTIG analyst Dane Leone sees new reason to step away from the sidelines on Kite Pharma Inc (NASDAQ:KITE), upgrading his rating from a …

Kite Pharma Inc (KITE) Gets Priority Review for Axicabtagene Ciloleucel from FDA

Kite Pharma Inc (NASDAQ:KITE) announced that the FDA has accepted for priority review the Biologics License Application (BLA) for axicabtagene ciloleucel. The submission follows …

Valeant Pharmaceuticals Intl Inc (VRX) Shows Signs of Stabilization, Kite Pharma Inc (KITE) Dives on Clinical Setback

Valeant Shows Signs of the Stabilization Valeant Pharmaceuticals Intl Inc (NYSE:VRX) investors are finally waking up from their nightmare, as the stock rockets 20% …

Kite Pharma Inc (KITE) Hits a Speed Bump

Yesterday, drug maker Kite Pharma Inc (NASDAQ:KITE) disclosed the death of a patient who was treated with KTE-C19, the company’s CAR-T blood cancer drug, …

Kite Pharma Inc (KITE) Outlook Remains Positive: Top Analyst

Kite Pharma Inc (NASDAQ:KITE) shares tumbled nearly 13% to $70.99 in Monday’s trading session, after the drug maker announced a grade 5 case …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts